Norovirus is the leading cause of gastroenteritis and is responsible for hundreds of thousands of deaths every year. However, ...

The rollout of a type of genetic technology called a gene drive for tackling malaria could be edging closer after a lab study ...

DENVER, Dec. 10, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market ...

On November 25, 2025, Sarepta Therapeutics filed two petitions for inter partes review (“IPR”) challenging Genzyme’s patents relating to ...

Dyadic International, Inc. ( DYAI) IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 December 9, 2025 9:30 AM EST Good day, and welcome to the iAcessAlpha Virtual Best Ideas winter ...

A cutting-edge base-edited CAR T-cell therapy is opening a revolutionary new frontier for patients battling aggressive T-cell ...

First anthrax vaccine developed using recombinant DNA technology- Annual production capacity of up to 10 million doses at GC ...

According to Research by SNS Insider, the U.S. Peptide Therapeutics Market is Set to Reach USD 35.71 Billion by 2032, Supported by Rising Adoption of Precision Biologics and Advances in Peptide ...

A Nobel laureate, he identified an enzyme that cuts DNA, laying the groundwork for milestones in scientific research and ...

The protein, reverse transcriptase, has become an essential tool for making DNA copies of RNA.

Plasmid Purification Market to reach USD 6.6 Bn by 2035 at 12.3% CAGR, Driven by rising gene therapy demand, mRNA vaccines, ...

FDA cleared Itvisma as the first gene-replacement therapy available to people 2 and older with the rare muscle-weakening condition. ・Phase III data showed improved or stabilized motor function with a ...